Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GLB-COV2-043
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against COVID-19.
Brand Name : GLB-COV2-043
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 01, 2023
Lead Product(s) : GLB-COV2-043
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Under the collaboration, GreenLight Biosciences and Epivax Therapeutics will design and develop new personalized mRNA-based cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 09, 2023
Lead Product(s) : mRNA-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
NIH, GreenLight Biosciences to Collaborate On COVID-19 Vaccine Development for New Variants
Details : GreenLight—in collaboration with the Vaccine Research Center, part of NIH’s National Institute of Allergy and Infectious Diseases—will co-design and test mRNA vaccines against coronaviruses with the goal of developing vaccines that confer a more du...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
July 29, 2022
Lead Product(s) : mRNA-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : mRNA-based Therapy
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Serum Institute of India and GreenLight Biosciences Multitarget Licensing Agreement
Details : Serum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles. Serum Institute of India also has an option to expand the relationship further for two additional vaccine or therapeutic targets.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 14, 2022
Lead Product(s) : mRNA-based Therapy
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : mRNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Flu Lab
Deal Size : $17.0 million
Deal Type : Financing
Details : This round of financing is aimed at establishing a scaled process under cGMP, capable of supporting clinical development and enabling the production of billions of doses of COVID-19 vaccine using GreenLight's proprietary bioprocessing technology.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 12, 2020
Lead Product(s) : mRNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Flu Lab
Deal Size : $17.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?